

Karyopharm Therapeutics Inc.  
Form 8-K  
June 21, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 19, 2018**

**Karyopharm Therapeutics Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-36167**  
**(Commission**  
**File Number)**

**26-3931704**  
**(IRS Employer**  
**Identification No.)**

**85 Wells Avenue, 2nd Floor**  
**Newton, Massachusetts**  
**(Address of Principal Executive Offices)**

**02459**  
**(Zip Code)**

**Registrant's telephone number, including area code: (617) 658-0600**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

Karyopharm Therapeutics Inc. (the Company) held its 2018 Annual Meeting of Stockholders on June 19, 2018. The following is a summary of the matters voted on at that meeting.

1. The Company's stockholders elected Deepika R. Pakianathan, Ph.D. as a class II director to serve until the 2021 Annual Meeting of Stockholders, to hold office until her successor has been duly elected and qualified. The results of the stockholders' vote with respect to the election of such class II director were as follows:

	<b>Votes For</b>	<b>Votes Withheld</b>	<b>Broker Non-Votes</b>
Deepika R. Pakianathan, Ph.D.	33,227,168	112,061	4,528,623

2. The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. The results of the stockholders' vote with respect to such ratification were as follows:

<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstaining</b>
37,843,019	16,309	8,524

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KARYOPHARM THERAPEUTICS INC.

Date: June 21, 2018

By: /s/ Christopher B. Primiano  
Christopher B. Primiano  
Executive Vice President, Chief Business Officer,  
General Counsel and Secretary